Factors contributing to tumor shrinkage after peptide receptor radionuclide therapy in patients with unresectable neuroendocrine tumors

被引：0

作者：

Noritoshi, K. ^{[1
]}

Sho, H. ^{[1
]}

Wild, D. ^{[2
]}

Kaul, F. ^{[2
]}

Motokazu, S. ^{[1
]}

Naoki, O. ^{[1
]}

Risa, F. ^{[1
]}

Akihiro, S. ^{[1
]}

Motohiko, T. ^{[1
]}

Shoko, T. ^{[1
]}

Yasushi, I ^{[1
]}

机构：

[1] Yokohama City Univ, Yokohama, Kanagawa, Japan

[2] Univ Hosp Basel, Basel, Switzerland

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷

关键词：

lesion-based analysis; neuroendocrine tumor; peptide receptor radionuclide therapy;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H29

引用

页码：201 / 201

页数：1

共 50 条

[41] Safety and efficacy of peptide receptor radionuclide therapy in treating high-risk patients with extensive neuroendocrine tumors [J].

Alsadik, S. R. ;

Gnanasegaran, G. ;

Chen, L. ;

Toumpanakis, C. ;

Caplin, M. ;

Navalkissoor, S. .

JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 :172-172

[42] Neoadjuvant Downsizing by Internal Radiation A Case for Preoperative Peptide Receptor Radionuclide Therapy in Patients With Pancreatic Neuroendocrine Tumors [J].

Ezziddin, Samer ;

Lauschke, Holger ;

Schaefers, Michael ;

Meyer, Carsten ;

van Essen, Martijn ;

Biersack, Hans-Juergen ;

Kwekkeboom, Dik J. ;

Ahmadzadehfar, Hojjat .

CLINICAL NUCLEAR MEDICINE, 2012, 37 (01) :102-104

[43] Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms [J].

Kaemmerer, Daniel ;

Twrznik, Matthias ;

Kulkarni, Harshad R. ;

Horsch, Dieter ;

Sehner, Susanne ;

Baum, Richard P. ;

Hommann, Merten .

ANNALS OF SURGERY, 2021, 274 (01) :E45-E53

[44] Complete Remission Upon Peptide Receptor Radionuclide Therapy in a G2 Pancreatic Neuroendocrine Tumor [J].

Weich, Alexander ;

Serfling, Sebastian E. ;

Yi, Heqing ;

Buck, Andreas K. ;

Higuchi, Takahiro ;

Werner, Rudolf A. .

CLINICAL NUCLEAR MEDICINE, 2023, 48 (04) :335-336

[45] Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor [J].

Kucukyurt, Selin ;

Yagiz Ozogul, Yeliz ;

Ercaliskan, Abdulkadir ;

Kabasakal, Levent ;

Eskazan, Ahmet Emre .

CANCER REPORTS, 2020, 3 (05)

[46] Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging [J].

Giovanni Paganelli ;

Maddalena Sansovini ;

Emanuela Scarpi .

European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 :1777-1778

[47] Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors [J].

Kwekkeboom, Dik J. ;

de Herder, Wouter W. ;

Krenning, Eric P. .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (01) :173-+

[48] Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review [J].

Camus, Baptiste ;

Cottereau, Anne-Segolene ;

Palmieri, Lola-Jade ;

Dermine, Solene ;

Tenenbaum, Florence ;

Brezault, Catherine ;

Coriat, Romain .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) :1-18

[49] The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future [J].

Liberini, Virginia ;

Huellner, Martin W. ;

Grimaldi, Serena ;

Finessi, Monica ;

Thuillier, Philippe ;

Muni, Alfredo ;

Pellerito, Riccardo E. ;

Papotti, Mauro G. ;

Piovesan, Alessandro ;

Arvat, Emanuela ;

Deandreis, Desiree .

DIAGNOSTICS, 2020, 10 (12)

[50] Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases [J].

Ngongoni, Rejoice ;

Visser, Brendan .

CANCERS, 2022, 14 (20)

← 1 2 3 4 5 →